Open AccessTREATMENT OF STABILE ISCHEMIC HEART DISEASE: IS CORONARY STENTING SUPERIOR OVER DRUG THERAPY?
Author(s) -
С. Г. Канорский,
Н. В. Смоленская
Publication year - 2019
Publication title -
kubanskij naučnyj medicinskij vestnik
Language(s) - English
Resource type - Journals
eISSN - 2541-9544
pISSN - 1608-6228
DOI - 10.25207/1608-6228-2019-26-1-196-208
Subject(s) - conventional pci , medicine , cardiology , percutaneous coronary intervention , revascularization , pharmacotherapy , coronary heart disease , myocardial infarction
The results of the most discussed randomized trials of percutaneous coronary intervention (PCI) in comparison with drug therapy (COURAGE and FAME 2) and PCI imitation (ORBITA) in patients with stable coronary heart disease are analyzed. Information on the ongoing ISCHEMIA trial is presented. Different points of view are compared concerning the results of the most important PCI research projects. Factors that can distort the results and the possibilities of their elimination are discussed. The main provisions of the American (2017) and European (2018) Guidelines on myocardial revascularization with a focus on PCI in patients with stable coronary heart disease are described. Conflict of interest: the authors declare no conflict of interest.